Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Correction to: Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma

Fig. 2

BTNL9 Expression and prognosis in LUAD. A BTNs expression panel in LUAD tissues compared with adjacent tissues in GEPIA database. B Correlation between BTNL8 and BTNL9 expression and LUAD clinical stages, N stage, and p53 mutation in the UALCAN database (BTNL8 expression compared with LUAD clinical stages (Normal-vs-Stage1, P = 1.01E-04; Normal-vs-Stage2, P = 7.08E-03; Normal-vs-Stage3, P = 1.36E-04; Normal-vs-Stage4, P = 1.78E-08), N stage (Normalvs-N0, P = 6.56E-04; Normal-vs-N1, P = 8.27E-10; Normal-vs-N2, P = 5.96E-04; Normal-vs-N3, P = 1.97E-10; N0-vs-N1, P = 3.27E-03; N0-vs-N3, P = 6.79E-04), and p53 status (Normal-vs-T P53-Mutant, P = 1.27E-06; Normal-vs-T P53-NonMutant, P = 1.80E-03). BTNL9 expression comparison with LUAD clinical stages (Normal-vsStage1, P = 1.21E-12; Normal-vs-Stage2, P = 3.60E-13; Normal-vs-Stage3, P = 2.40E-12; Normal-vs-Stage4, P = 2.25E-12), N stage (Normal-vs-N0, P = 1.08E-12; Normal-vs-N1, P = 1.85E-12; Normal-vs-N2, P = 1.02E-12; Normal-vs-N3, P = 1.67E-12; N0-vs-N1, P = 1.02E-03; N2-vs-N3, P = 3.01E-02), and P53 status (Normal-vs-T P53-Mutant, P = 1.85E-12; Normal-vs-T P53-NonMutant, P = 4.10E-12; T P53-Mutant-vs-T P53-NonMutant, P = 1.77E-04)). C Correlation between BTNL8 and BTNL9 expression with overall survival of LUAD using GEPIA database. D Correlation between BTNL9 expression and LUAD overall survival using OncoLnc, UALCAN, and KM plotter databases. *: P-value < 0.05; **: P-value < 0.01; ***: P-value < 0.001

Back to article page